- Preparation method of M-nitro - β β-hydroxyethyl sulfone (by machine translation)
-
The invention discloses a method for preparing M-nitro - β β-hydroxyethyl sulfone, belongs to the technical field of dye chemical intermediate manufacturing, and comprises the following steps: (1) adding an aqueous hydrazine hydrate solution, slowly or repeatedly adding m-nitrobenzenesulfonyl chloride; 40~70 °C) dropwise adding ethylene oxide, controlling 50~70 °C the temperature 0.5~1.5, and 2 using pH7.0~7.6 dilute sulfuric acid to maintain pH5.0~7.0, filtering, and obtaining m-hydroxyethyl sulfone. (Z - β β-hydroxyethyl sulfone). Compared with a traditional process for improving the high-salinity wastewater and the nunitz ? waste residue, the process is cleaner, environment-friendly; the process is simple, the required equipment is few, and the investment of equipment is greatly reduced; and the equipment investment can be greatly reduced. 20% 5 tonnes 98.5% 70 kg (by machine translation)
- -
-
Paragraph 0031; 0033-0036; 0040-0041; 0043-0044; 0046-0047
(2019/09/14)
-
- Synthesis of arylstannanes by palladium-catalyzed desulfitative coupling reaction of sodium arylsulfinates with distannanes
-
A novel Pd-catalyzed desulfitative cross-coupling reaction of sodium arylsulfinates with hexaalkyl distannanes is realized, allowing the facile synthesis of functionalized arylstannanes with moderate to excellent yields. The successful implement of gram-scale synthesis and tandem Stille coupling reaction demonstrates the potential applications of this method in organic synthesis.
- Lian, Chang,Yue, Guanglu,Zhang, Haonan,Wei, Liyan,Liu, Danyang,Liu, Sichen,Fang, Huayi,Qiu, Di
-
supporting information
p. 4019 - 4023
(2018/10/04)
-
- MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
-
The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
- -
-
Page/Page column 905
(2021/02/10)
-
- Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
-
The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
- -
-
Paragraph 3888; 3889
(2016/05/02)
-
- Synthesis of oxindoles through silver-catalyzed trifluoromethylation-, difluoromethylation- and arylsulfonylation-cyclization reaction of N-arylacrylamides
-
Efficient synthesis of trifluoromethyl and difluoromethyl-substituted oxindoles was achieved by reacting Langlois reagent or Baran reagent with N-arylacrylamides. However, the reaction of aryl sulfinic acid sodium salts with N-arylacrylamides did not give the desulfinative products, instead, aryl sulfonated products were produced. Copyright
- Liu, Jidan,Zhuang, Shaobo,Gui, Qingwen,Chen, Xiang,Yang, Zhiyong,Tan, Ze
-
supporting information
p. 3196 - 3202
(2014/06/09)
-
- BENZOFURO[3,2-c] PYRIDINES AND RELATED ANALOGS AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS FOR THE TREATMENT OF OBESITY, METABOLIC SYNDROME, COGNITION AND SCHIZOPHRENIA
-
The present invention relates to benzofuro[3,2-c]pyridine and azepine analogs as serotonin sub-type 6 (5-HT6) modulators, pharmaceutical compositions including these compounds, methods of preparation, and use thereof. These compounds are useful in the treatment of central nervous system disorders including obesity, metabolic syndrome, cognition, schizophrenia, attention deficit hyperactivity disorder, bipolar disorder, rare and orphan diseases, and sleep disorders. The subject compounds have the structure of formula (I) with the substituents being described herein.
- -
-
Page/Page column 32
(2012/07/28)
-
- EPIMINOCYCLOALKYL(B)INDOLE DERIVATIVES AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS AND USES THEREOF
-
The present invention relates to epiminocycloalkyl[b]indole derivatives as serotonin sub-type 6 (5-HT6) modulators, pharmaceutical compositions including these compounds, and methods of preparation and use thereof. These compounds are useful in the treatment of central nervous system disorders including obesity, metabolic syndrome, cognition, and schizophrenia. The subject compounds have the structure of formula (I), with the substituents being described herein.
- -
-
Page/Page column 37
(2011/04/26)
-